Guest Editorial

Dextropropoxyphene is dead? Long live....

Anthony G Beeton
Southern African Journal of Anaesthesia and Analgesia | Vol 17, No 4 | a472 | DOI: https://doi.org/10.1080/22201173.2011.10872791 | © 2011 Anthony G Beeton | This work is licensed under CC Attribution 4.0
Submitted: 03 November 2025 | Published: 01 January 2011

About the author(s)

Anthony G Beeton,, South Africa

Full Text:

PDF (117KB)

Abstract

On 20 April 2011, the Medicines Control Council (MCC) announced its decision to withdraw all dextropropoxyphene-(DPP-) containing products from the South African market within three months, because of stated safety risks and an insufficiently weighted risk-benefit profile. These risks refer to dose-related cardiac conduction abnormalities associated with QT prolongation, provoked by the main metabolite of DPP, norpropoxyphene. Cases of fatal arrhythmias have been described.

Keywords

Dextropropoxyphene; withdrawn;

Metrics

Total abstract views: 226
Total article views: 34

 

Crossref Citations

1. A randomised clinical trial comparing the analgesic and anxiolytic efficacy and tolerability of Stilpane® and Tramacet® after third molar extraction
K Outhoff, JM Dippenaar, M Nell, M Royds, OBW Greeff
Southern African Journal of Anaesthesia and Analgesia  vol: 21  issue: 2  first page: 40  year: 2015  
doi: 10.1080/22201181.2015.1028229